Innate Immunity against Cryptococcus, from Recognition to Elimination
- PMID: 29518906
- PMCID: PMC5872336
- DOI: 10.3390/jof4010033
Innate Immunity against Cryptococcus, from Recognition to Elimination
Abstract
Cryptococcus species, the etiological agents of cryptococcosis, are encapsulated fungal yeasts that predominantly cause disease in immunocompromised individuals, and are responsible for 15% of AIDS-related deaths worldwide. Exposure follows the inhalation of the yeast into the lung alveoli, making it incumbent upon the pattern recognition receptors (PRRs) of pulmonary phagocytes to recognize highly conserved pathogen-associated molecular patterns (PAMPS) of fungi. The main challenges impeding the ability of pulmonary phagocytes to effectively recognize Cryptococcus include the presence of the yeast's large polysaccharide capsule, as well as other cryptococcal virulence factors that mask fungal PAMPs and help Cryptococcus evade detection and subsequent activation of the immune system. This review will highlight key phagocyte cell populations and the arsenal of PRRs present on these cells, such as the Toll-like receptors (TLRs), C-type lectin receptors, NOD-like receptors (NLRs), and soluble receptors. Additionally, we will highlight critical cryptococcal PAMPs involved in the recognition of Cryptococcus. The question remains as to which PRR-ligand interaction is necessary for the recognition, phagocytosis, and subsequent killing of Cryptococcus.
Keywords: C-type lectin receptors (CLRs); Cryptococcus deneoformans; Cryptococcus gattii; Cryptococcus neoformans; NOD-like receptors (NLRs); Toll-like receptors (TLRs); host–pathogen interactions; innate immune response; pathogen-associated molecular patterns (PAMPs); pattern recognition receptors (PRRs).
Conflict of interest statement
The authors declare no conflicts of interest. The funders had no role in the decision to publish, or in the preparation of the manuscript.
Figures


Similar articles
-
[Recognition of Cryptococcus neoformans by Pattern Recognition Receptors and its Role in Host Defense to This Infection].Med Mycol J. 2017;58(3):J83-J90. doi: 10.3314/mmj.17.011. Med Mycol J. 2017. PMID: 28855484 Review. Japanese.
-
PAMPs and Host Immune Response in Cryptococcal Infection.Med Mycol J. 2022;63(4):133-138. doi: 10.3314/mmj.22.005. Med Mycol J. 2022. PMID: 36450565 Review.
-
Detection and Quantification of Cryptococcus Uptake by Phagocytic Cells Using Imaging Flow Cytometry.Methods Mol Biol. 2024;2775:195-209. doi: 10.1007/978-1-0716-3722-7_13. Methods Mol Biol. 2024. PMID: 38758319
-
Cryptococcus and Phagocytes: Complex Interactions that Influence Disease Outcome.Front Microbiol. 2016 Feb 9;7:105. doi: 10.3389/fmicb.2016.00105. eCollection 2016. Front Microbiol. 2016. PMID: 26903984 Free PMC article. Review.
-
Innate Immune Responses to Fungal Allergens.Curr Allergy Asthma Rep. 2016 Sep;16(9):62. doi: 10.1007/s11882-016-0643-4. Curr Allergy Asthma Rep. 2016. PMID: 27520938 Review.
Cited by
-
Adjuvant Curdlan Contributes to Immunization against Cryptococcus gattii Infection in a Mouse Strain-Specific Manner.Vaccines (Basel). 2022 Apr 15;10(4):620. doi: 10.3390/vaccines10040620. Vaccines (Basel). 2022. PMID: 35455369 Free PMC article.
-
Host Genetics Takes a Toll on Immunity to Cryptococcus.EBioMedicine. 2018 Nov;37:9-10. doi: 10.1016/j.ebiom.2018.10.064. Epub 2018 Nov 1. EBioMedicine. 2018. PMID: 30391494 Free PMC article. No abstract available.
-
An immunoinformatics and extensive molecular dynamics study to develop a polyvalent multi-epitope vaccine against cryptococcosis.PLoS One. 2024 Dec 31;19(12):e0315105. doi: 10.1371/journal.pone.0315105. eCollection 2024. PLoS One. 2024. Retraction in: PLoS One. 2025 Apr 4;20(4):e0322316. doi: 10.1371/journal.pone.0322316. PMID: 39739919 Free PMC article. Retracted.
-
Host, pathogenic fungi and the microbiome: A genetic triangle in infection.Front Immunol. 2023 Jan 17;13:1078014. doi: 10.3389/fimmu.2022.1078014. eCollection 2022. Front Immunol. 2023. PMID: 36733397 Free PMC article. No abstract available.
-
Clinical characteristics of pulmonary cryptococcosis coexisting with lung adenocarcinoma: Three case reports.World J Clin Cases. 2020 Dec 26;8(24):6444-6449. doi: 10.12998/wjcc.v8.i24.6444. World J Clin Cases. 2020. PMID: 33392329 Free PMC article.
References
-
- Perfect J.R., Dismukes W.E., Dromer F., Goldman D.L., Graybill J.R., Hamill R.J., Harrison T.S., Larsen R.A., Lortholary O., Nguyen M.H., et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin. Infect. Dis. 2010;50:291–322. doi: 10.1086/649858. - DOI - PMC - PubMed
-
- Rajasingham R., Smith R.M., Park B.J., Jarvis J.N., Govender N.P., Chiller T.M., Denning D.W., Loyse A., Boulware D.R. Global burden of disease of HIV-associated cryptococcal meningitis: An updated analysis. Lancet Infect. Dis. 2017;17:873–881. doi: 10.1016/S1473-3099(17)30243-8. - DOI - PMC - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources